RGD Reference Report - MicroRNA-645 represses hepatocellular carcinoma progression by inhibiting SOX30-mediated p53 transcriptional activation. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

MicroRNA-645 represses hepatocellular carcinoma progression by inhibiting SOX30-mediated p53 transcriptional activation.

Authors: Tao, Jie  Liu, Zhikui  Wang, Yufeng  Wang, Liang  Yin, Guozhi  Yang, Wei  Tu, Kangsheng  Liu, Qingguang 
Citation: Tao J, etal., Int J Biol Macromol. 2019 Jan;121:214-222. doi: 10.1016/j.ijbiomac.2018.10.032. Epub 2018 Oct 9.
RGD ID: 151660341
Pubmed: PMID:30312695   (View Abstract at PubMed)
DOI: DOI:10.1016/j.ijbiomac.2018.10.032   (Journal Full-text)

Amount of evidence demonstrate that aberrant microRNAs (miRNAs) are involved in tumorigenesis and progression in hepatocellular carcinoma (HCC). Among them, miR-645 is recently recognized as cancer-related miRNA and its significance in HCC remains largely unknown. In this study, we reported for the first that miR-645 expression was markedly elevated in HCC tissues and cell lines, and its up-regulation was associated with malignant clinical features, including tumor size and venous infiltration and poor prognosis. Our data revealed that miR-645 promoted cell proliferation, colony formation and inhibited apoptosis by gain- and loss-of function experiments in vitro. In vivo assays showed that miR-645 overexpression enhanced tumor growth. Moreover, miR-645 directly bound to the SOX30 3'-UTR and post-transcriptionally repressed SOX30 expression in HCC cells. Furthermore, miR-645 inversely correlated with SOX30 expression in HCC tissues. Restoration of SOX30 expression at least partially abolished the biological effects of miR-645 on HCC cells. SOX30 regulated HCC progression through aberrant activation of p53 by directly binding to its promoter. Taken together, this research supports the first evidence that miR-645 exerts an oncogenic role in HCC progression and may be a therapeutic target for HCC treatment.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
SOX30Humanhepatocellular carcinoma disease_progressionIEP  RGD 
SOX30Humanhepatocellular carcinoma exacerbatesIDA  RGD 
Sox30Mousehepatocellular carcinoma disease_progressionISOSOX30 (Homo sapiens) RGD 
Sox30Mousehepatocellular carcinoma exacerbatesISOSOX30 (Homo sapiens) RGD 
Sox30Rathepatocellular carcinoma disease_progressionISOSOX30 (Homo sapiens) RGD 
Sox30Rathepatocellular carcinoma exacerbatesISOSOX30 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Sox30  (SRY-box transcription factor 30)

Genes (Mus musculus)
Sox30  (SRY (sex determining region Y)-box 30)

Genes (Homo sapiens)
SOX30  (SRY-box transcription factor 30)


Additional Information